Get the Stockscreener App
1.56
9.09%
0.13
After Hours:
1.50
-0.06
-3.85%
Invivyd Inc stock is traded at $1.56, with a volume of 2.11M.
It is up +9.09% in the last 24 hours and down -8.77% over the past month.
Invivyd Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), received emergency use authorization from the U.S. FDA for the pre-exposure prevention of COVID-19 in certain immunocompromised individuals. The company is also developing next-generation antibody candidates, including VYD2311 for COVID-19 and VBY329 for RSV infections, while continuing research on additional antibodies targeting other viral diseases such as measles.
See More
Previous Close:
$1.43
Open:
$1.46
24h Volume:
2.11M
Relative Volume:
0.66
Market Cap:
$440.85M
Revenue:
$53.43M
Net Income/Loss:
$-52.49M
P/E Ratio:
-4.3466
EPS:
-0.3589
Net Cash Flow:
$-58.29M
1W Performance:
+3.31%
1M Performance:
-8.77%
6M Performance:
+36.84%
1Y Performance:
+136.47%
1-Day Range:
$1.45
$1.59
1-Week Range:
$1.37
$1.59
52-Week Range:
$0.46
$3.0699
Invivyd Inc Stock (IVVD) Company Profile
Name
Invivyd Inc
Sector
Industry
Phone
(781) 819-0080
Address
209 CHURCH STREET, NEW HAVEN
Compare IVVD vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IVVD
Invivyd Inc
|
1.56 | 404.11M | 53.43M | -52.49M | -58.29M | -0.3589 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Invivyd Inc Stock (IVVD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-22-25 | Initiated | BTIG Research | Buy |
| Nov-25-25 | Downgrade | D. Boral Capital | Buy → Hold |
| Oct-06-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-05-24 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-26-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-19-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| May-01-23 | Initiated | H.C. Wainwright | Buy |
View All
Invivyd Inc Stock (IVVD) Latest News
Analysis Recap: What is the target price for Invivyd Inc stockTrade Signal Summary & Daily Stock Trend Watchlist - baoquankhu1.vn
Insider Buy: How liquid is Invivyd Inc stock2026 Breakouts & Breakdowns & Weekly Top Performers Watchlists - baoquankhu1.vn
Aug Gainers: What is the target price for Invivyd Inc stock2026 Gainers & Daily Momentum Trading Reports - baoquankhu1.vn
Invivyd: A Logical Bull Thesis With A Major Catalyst Approaching (NASDAQ:IVVD) - Seeking Alpha
Inflation Data: Is Invivyd Inc exposed to currency risksWeekly Gains Report & AI Enhanced Trading Alerts - baoquankhu1.vn
Invivyd (IVVD) Q4 2025 Earnings Call Transcript - AOL.com
FY2027 Earnings Estimate for Invivyd Issued By HC Wainwright - MarketBeat
Invivyd Earnings Call Highlights Pivotal Trial Momentum - The Globe and Mail
Invivyd (NASDAQ:IVVD) Stock Price Up 6.3%Still a Buy? - MarketBeat
Invivyd appoints Michael Mina as chief medical officer - Investing.com Nigeria
Invivyd, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:IVVD) 2026-03-08 - Seeking Alpha
Invivyd, Inc. (NASDAQ:IVVD) Q4 2025 Earnings Call Transcript - Insider Monkey
Invivyd, Inc. (NASDAQ:IVVD) Receives Average Rating of "Hold" from Analysts - MarketBeat
Invivyd Q4 2025 slides: revenue surges 31%, pipeline advances By Investing.com - Investing.com Canada
Invivyd earnings beat by $0.11, revenue topped estimates - Investing.com Australia
Invivyd Q4 Earnings Call Highlights - MarketBeat
Michael Mina Appointed Chief Medical Officer at Invivyd - geneonline.com
Invivyd appoints Michael Mina as chief medical officer By Investing.com - Investing.com Australia
Invivyd Q4 2025 slides: revenue surges 31%, pipeline advances - Investing.com Nigeria
Invivyd Names Michael Mina Chief Medical Officer - Contract Pharma
Invivyd, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Invivyd Appoints Michael Mina, M.D., Ph.D. as Chief Medical Officer - citybiz
Earnings call transcript: Invivyd Q4 2025 shows robust growth and strategic expansion - Investing.com
Invivyd Advances VYD2311 With Key Phase 3 Alignments - TipRanks
Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer - The Globe and Mail
Invivyd 2025 10-K: Revenue $53.4M, Net Loss $52.5M - TradingView
Invivyd FY revenue rises; operating expenses cut sharply - TradingView
Michael Mina named chief medical officer, Invivyd, Inc. announces - Traders Union
Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates - The Manila Times
COVID testing voice Michael Mina now steering antibody drug effort - Stock Titan
Invivyd's Fourth Quarter 2025: Market Achievements Reflected in Valuation, Uneven Pipeline Risk - Bitget
An Overview of Invivyd's Earnings - Benzinga
Invivyd, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Invivyd (IVVD) to Release Earnings on Thursday - MarketBeat
Invivyd Inc expected to post a loss of 8 cents a shareEarnings Preview - TradingView
Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026 - The Manila Times
Invivyd (IVVD): Post-Data Plunge, Cash Runway And Next Catalysts For US Traders - AD HOC NEWS
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bitget
IVVD Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
New Invivyd staff get options on 192,000 shares at $1.69 each - Stock Titan
Invivyd (NASDAQ:IVVD) Earns "Buy" Rating from BTIG Research - MarketBeat
New study maps COVID protection to antibody levels, not variants - Stock Titan
New Publication Demonstrates Variant-Agnostic Correlate of Protection from COVID-19 for Invivyd Monoclonal Antibody, Useful for Understanding of and Confidence in COVID-19 Antibodies - The Globe and Mail
Aug Breakouts: Is Eaton Vance Senior Income Trust gaining market share2025 Bull vs Bear & Real-Time Price Movement Reports - baoquankhu1.vn
Lobbying Update: $20,000 of INVIVYD INC. lobbying was just disclosed - Quiver Quantitative
Invivyd (IVVD) CHRO Green sells $63k in stock after option exercise - Investing.com India
Invivyd (IVVD) CFO Duke sells shares worth $63,350 - Investing.com UK
Invivyd Inc Stock (IVVD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):